Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer

Molecular Cancer

Sarah Rahman¹  Mohammed Hafiz Uddin²  Suresh Balasubramanian²  Misako Nagasaka²  Asfar S. Azmi²  Ammar Sukari²  Mohammed Najeeb Al-Hallak² 

[1] Department of Cell and Molecular Biology, Grand Valley State University;Department of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute;

关键词: Liquid biopsy;    Circulating nucleic acid;    ctDNA;    ctRNA;    miRNA;    lncRNA;   

DOI  :  10.1186/s12943-021-01371-1

来源: DOAJ

【 摘 要 】

Abstract Liquid biopsy is now considered a valuable diagnostic tool for advanced metastatic non-small cell lung cancer (NSCLC). In NSCLC, circulating tumor DNA (ctDNA) analysis has been shown to increase the chances of identifying the presence of targetable mutations and has been adopted by many clinicians owing to its low risk. Serial monitoring of ctDNA may also help assess the treatment response or for monitoring relapse. As the presence of detectable plasma ctDNA post-surgery likely indicates residual tumor burden, studies have been performed to quantify plasma ctDNA to assess minimal residual disease (MRD) in early-stage resected NSCLC. Most data on utilizing liquid biopsy for monitoring MRD in early-stage NSCLC are from small-scale studies using ctDNA. Here, we review the recent research on liquid biopsy in NSCLC, not limited to ctDNA, and focus on novel methods such as micro RNAs (miRNA) and long non-coding (lncRNA).

【 授权许可】

Unknown